A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Featured News
EU Weighs Potential Role as Competing Bids for Warner Bros. Discovery Intensify
Dec 10, 2025 by
CPI
Trump Throws Curveball at Netflix Deal: ‘CNN Must Be Part of the Sale’
Dec 10, 2025 by
CPI
EU Court Cuts Intel Fine but Confirms Antitrust Breach
Dec 10, 2025 by
CPI
Prediction Markets Emerging as New Flash Point Between Federal and State Regulators
Dec 10, 2025 by
CPI
CoStar Urges Supreme Court to Block Antitrust Claims in CREXi Fight
Dec 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Intellectual Property
Nov 19, 2025 by
CPI
Dealing in Intellectual Property: IP Justifications and Defenses in Digital Markets Cases
Nov 19, 2025 by
Jennifer Dixton
The Evolving Role of Innovation Theories of Harm in the Antitrust Analysis of Life Science Mergers
Nov 19, 2025 by
Michelle Yost Hale, Matthew D. McDonald & Merrill Stovroff
Who Can Fix It? Antitrust, IP Rights, and the Right to Repair
Nov 19, 2025 by
Rosa M. Morales
Copyright, Antitrust, and the Politics of Generative AI
Nov 19, 2025 by
Daryl Lim